Neurocrine Biosciences (NBIX) Earns News Sentiment Rating of 0.14

News coverage about Neurocrine Biosciences (NASDAQ:NBIX) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a news impact score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.8213924243208 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Neurocrine Biosciences (NBIX) traded up $2.20 during trading hours on Friday, reaching $77.59. 926,413 shares of the company traded hands, compared to its average volume of 764,304. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a twelve month low of $37.56 and a twelve month high of $78.05. The firm has a market cap of $6,671.49, a P/E ratio of -34.95 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the business posted ($0.43) EPS. equities analysts predict that Neurocrine Biosciences will post -1.66 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the stock. Deutsche Bank restated a “buy” rating and issued a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Citigroup reiterated a “buy” rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Oppenheimer lifted their target price on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Robert W. Baird reiterated a “buy” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $58.00 target price on shares of Neurocrine Biosciences in a research report on Sunday, September 17th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Neurocrine Biosciences has an average rating of “Buy” and an average price target of $78.88.

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 2,955 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $75.00, for a total transaction of $221,625.00. Following the completion of the transaction, the insider now owns 16,112 shares in the company, valued at approximately $1,208,400. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Christopher Flint Obrien sold 6,925 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $61.04, for a total transaction of $422,702.00. Following the transaction, the insider now owns 55,898 shares of the company’s stock, valued at approximately $3,412,013.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,877 shares of company stock valued at $6,568,617. Company insiders own 4.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Neurocrine Biosciences (NBIX) Earns News Sentiment Rating of 0.14” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/30/neurocrine-biosciences-nbix-earns-news-sentiment-rating-of-0-14.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit